Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate

恩曲他滨/盐酸利匹韦林/富马酸替诺福韦二吡呋酯

Report date: 2025/03/19 16:22:34

Base Information

Drug NameEmtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate
Drug Alias NameTenofovir disoproxil fumarate/Emtricitabine and Rilpivirine hydrochloride恩曲利替盐酸利匹韦林恩曲他滨富马酸替诺福韦二吡呋酯Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine HydrochlorideRilpivirine hydrochloride - Tenofovir disoproxil fumarate - Emtricitabine mixt +[11] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHuman immunodeficiency virus type 1 reverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2011/08/10
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsYes EmtricitabineRilpivirine HydrochlorideTenofovir Disoproxil Fumarate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences IncJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineGilead Sciences International LtdGilead Sciences Inc
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR08
Related LinksWikipediaKEGG